Abstract: A method for determining the type of a nucleotide on a nucleic acid sequence to be analyzed, and a nucleic acid sequencing method. In the method, at least one modified nucleotide for nucleic acid synthesis is separated from a nucleic acid sequence to be analyzed and other components on both sides of a membrane; when the modified nucleotide is transferred to the other side of the membrane under the action of an electric field by means of a nanopore embedded on the membrane, a synthesis reaction is conducted; moreover, the type of a base of the nucleotide is determined according to the change of the electrical properties of the nanopore in the process of the modified nucleotide is transferred by the nanopore, so as to implement sequencing.

Abstract: Provided are a nanopore preparation and detection method and detection apparatus thereof. The method comprises: forming a nanopore by aggregating a plurality of protein monomers, with a signal detection region of the nanopore being formed in a narrow passage portion of the nanopore; and forming a positive charge cluster in the signal detection region of the nanopore, wherein the charge interaction between the positive charge cluster and negatively charged single molecule analytes that pass through the nanopore can lengthen the residence time of the single molecule analytes in the nanopore. Accordingly, the effective detection of analytes at a single-molecular level is realized, such that single molecule analytes that cannot generate an effective detection signal due to an interaction time with a. nanopore being too short can be effectively detected, the prevalence of single molecule analytes can be significantly improved, and different analytes and detection requirements are accommodated.

Abstract: Disclosed in the embodiments of the present application are a microelectrode of a gene sequencing chip, a manufacturing method therefor, and a gene sequencing chip. The microelectrode comprises a substrate, a current collector layer formed on the substrate, and an electrode layer formed on the current collector layer; the current collector layer comprises a transition metal thin film or a nitride thin film thereof or a composite thin film of a transition metal and nitride thereof, and the electrode layer comprises a nitrogen oxide thin film of the transition metal, which is formed on the transition metal thin film or the nitride thin film thereof or the composite thin film of the transition metal and nitride thereof The embodiments of the present application improve the per unit area voltage driving capabilities of a microelectrode in a gene sequencing chip, can meet requirements for an ultra-high number of cycles, and improve the throughput and stability of a gene sequencing chip.

Abstract: Disclosed herein are anti-Claudin 18.2 antibodies and pharmaceutical compositions comprising the same. In some embodiments, also described herein are methods of treating a subject having a cancer with an anti-Claudin 18.2 antibody and methods of inducing cell kill effect with an anti-Claudin 18.2 antibody.

Abstract: Provided are a sodium salt of a uric acid transporter inhibitor and a crystalline form thereof, In particular, provided are a uric acid transporter (URAT1) inhibitor 1-((6-bromo-quinoline-4-yl)thio)cyclobutyl sodium formate (the compound of formula (I)), a crystal form I, and preparation method thereof. The obtained crystal form I of the compound of formula (I) has a good crystal form stability and chemical stability, and the crystallization solvent used has a low toxicity and low residue, and can be better used in clinical treatment.

Abstract: The present invention is directed to particular antibodies and fragments thereof that find use in the detection, prevention and treatment of diseases and disorders associated with abnormal angiogenesis. In particular, these antibodies detect tumor endothelial marker 8 (TEM8) in its native and cell-surface expressed form. Also disclosed are improved methods for producing monoclonal antibodies, as well as pharmaceutical compositions and kits.

Abstract: Provided are a sodium salt of a uric acid transporter inhibitor and a crystalline form thereof, In particular, provided are a uric acid transporter (URAT1) inhibitor 1-((6-bromo-quinoline-4-yl)thio)cyclobutyl sodium formate (the compound of formula (I)), a crystal form I, and preparation method thereof. The obtained crystal form I of the compound of formula (I) has a good crystal form stability and chemical stability, and the crystallization solvent used has a low toxicity and low residue, and can be better used in clinical treatment.

Abstract: Provided are a sodium salt of a uric acid transporter inhibitor and a crystalline form thereof, In particular, provided are a uric acid transporter (URAT1) inhibitor 1-((6-bromo-quinoline-4-yl)thio)cyclobutyl sodium formate (the compound of formula (I)), a crystal form I, and preparation method thereof. The obtained crystal form I of the compound of formula (I) has a good crystal form stability and chemical stability, and the crystallization solvent used has a low toxicity and low residue, and can be better used in clinical treatment.

Abstract: Provided are a sodium salt of a uric acid transporter inhibitor and a crystalline form thereof, In particular, provided are a uric acid transporter (URAT1) inhibitor 1-((6-bromo-quinoline-4-yl)thio)cyclobutyl sodium formate (the compound of formula (I)), a crystal form I, and preparation method thereof. The obtained crystal form I of the compound of formula (I) has a good crystal form stability and chemical stability, and the crystallization solvent used has a low toxicity and low residue, and can be better used in clinical treatment.

Abstract: The present invention is directed to particular antibodies and fragments thereof that find use in the detection, prevention and treatment of diseases and disorders associated with abnormal angiogenesis. In particular, these antibodies detect tumor endothelial marker 8 (TEM8) in its native and cell-surface expressed form. Also disclosed are improved methods for producing monoclonal antibodies, as well as pharmaceutical compositions and kits.

Abstract: The present invention is directed to particular antibodies and fragments thereof that find use in the detection, prevention and treatment of diseases and disorders associated with abnormal angiogenesis. In particular, these antibodies detect tumor endothelial marker 8 (TEM8) in its native and cell-surface expressed form. Also disclosed are improved methods for producing monoclonal antibodies, as well as pharmaceutical compositions and kits.